In case you missed it: August 16 to August 20
It was a busy week for the Contemporary OB/GYN team.
This week's top articles included:
FDA accepts pembrolizumab as single agent for treatment of advanced endometrial cancer
The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
New biomarker could predict immunotherapy benefit in breast cancer
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
Hormonal intravaginal rings could facilitate combination therapies for several conditions
“Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects,” wrote the authors.
New Hampshire's abortion restrictions
We spoke with Editorial Board member Ilana Cass, MD, about her opinion of her state's latest abortion restrictions.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
